tradingkey.logo

Merck & Co Inc

MRK
121.930USD
+2.180+1.82%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
303.28BMarktkapitalisierung
16.75KGV TTM

Merck & Co Inc

121.930
+2.180+1.82%

mehr Informationen über Merck & Co Inc Unternehmen

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Merck & Co Inc Informationen

BörsenkürzelMRK
Name des UnternehmensMerck & Co Inc
IPO-datumFeb 06, 2077
CEODavis (Robert M)
Anzahl der mitarbeiter75000
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse126 East Lincoln Avenue
StadtRAHWAY
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl07065
Telefon19087404000
Websitehttps://www.merck.com/
BörsenkürzelMRK
IPO-datumFeb 06, 2077
CEODavis (Robert M)

Führungskräfte von Merck & Co Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
491.04K
+47434.00%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
199.21K
+13880.00%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
100.06K
+20469.00%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
95.21K
+9865.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
65.00K
+11583.00%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
28.61K
+5703.00%
Ms. Patricia F. Russo
Ms. Patricia F. Russo
Independent Director
Independent Director
13.15K
--
Mr. Thomas Henry (Tom) Glocer, J.D.
Mr. Thomas Henry (Tom) Glocer, J.D.
Lead Independent Director
Lead Independent Director
5.10K
--
Mr. Inge G. Thulin
Mr. Inge G. Thulin
Independent Director
Independent Director
2.93K
--
Ms. Pamela J. Craig
Ms. Pamela J. Craig
Independent Director
Independent Director
1.72K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Robert M. (Rob) Davis
Mr. Robert M. (Rob) Davis
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
491.04K
+47434.00%
Mr. Sanat Chattopadhyay
Mr. Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Executive Vice President and President - Merck Manufacturing Division
199.21K
+13880.00%
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Executive Vice President, President - Merck Research Laboratories
Executive Vice President, President - Merck Research Laboratories
100.06K
+20469.00%
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Senior Vice President, Chief Marketing Officer - Human Health
95.21K
+9865.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Executive Vice President, General Counsel
Executive Vice President, General Counsel
65.00K
+11583.00%
Mr. Joseph Edward Romanelli
Mr. Joseph Edward Romanelli
Senior Vice President, President - MSD International Human Health
Senior Vice President, President - MSD International Human Health
28.61K
+5703.00%

Umsatzaufteilung

FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
10.01B
0.00%
Europe, Middle East and Africa
3.68B
0.00%
Latin America
905.00M
0.00%
Other
798.00M
0.00%
Asia Pacific (Other than China and Japan)
764.00M
0.00%
Andere
-16.16B
100.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Nov 17
Aktualisiert: Mon, Nov 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.20%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Andere
73.91%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.20%
BlackRock Institutional Trust Company, N.A.
5.69%
State Street Investment Management (US)
4.76%
Wellington Management Company, LLP
3.03%
Geode Capital Management, L.L.C.
2.41%
Andere
73.91%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.26%
Investment Advisor/Hedge Fund
26.83%
Research Firm
3.18%
Pension Fund
2.50%
Bank and Trust
2.13%
Sovereign Wealth Fund
1.55%
Hedge Fund
1.05%
Insurance Company
0.68%
Family Office
0.15%
Andere
19.67%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
5411
1.99B
80.21%
-57.82M
2025Q3
5358
2.02B
81.35%
-45.75M
2025Q2
5398
2.02B
80.82%
-16.42M
2025Q1
5446
2.05B
81.47%
-3.32M
2024Q4
5410
2.04B
80.88%
+11.87M
2024Q3
5200
2.01B
79.47%
-7.96M
2024Q2
5181
2.01B
79.28%
-4.86M
2024Q1
5154
2.00B
78.88%
-6.10M
2023Q4
5065
1.99B
78.60%
+584.81K
2023Q3
4871
1.98B
78.17%
-32.03M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
250.94M
10.11%
-809.74K
-0.32%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
141.15M
5.69%
-1.64M
-1.15%
Sep 30, 2025
State Street Investment Management (US)
118.18M
4.76%
-313.69K
-0.26%
Sep 30, 2025
Wellington Management Company, LLP
75.28M
3.03%
-1.58M
-2.05%
Sep 30, 2025
Geode Capital Management, L.L.C.
59.80M
2.41%
+846.19K
+1.44%
Sep 30, 2025
Charles Schwab Investment Management, Inc.
53.70M
2.16%
-166.01K
-0.31%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
36.11M
1.45%
+1.13M
+3.23%
Jun 30, 2025
Fidelity Management & Research Company LLC
27.61M
1.11%
-866.46K
-3.04%
Sep 30, 2025
Fisher Investments
24.07M
0.97%
-945.57K
-3.78%
Sep 30, 2025
BlackRock Asset Management Ireland Limited
22.50M
0.91%
-281.91K
-1.24%
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
VanEck Pharmaceutical ETF
16.09%
FT Vest DJIA Dogs 10 Target Income ETF
10.79%
First Trust NASDAQ Pharmaceuticals ETF
7.94%
Invesco Dow Jones Industrial Average Dividend ETF
6.94%
First Trust Morningstar Dividend Leaders Index Fund
5.39%
Coastal Compass 100 ETF
5.13%
Invesco Pharmaceuticals ETF
4.96%
VanEck Morningstar Wide Moat Value ETF
4.73%
Vaneck Durable High Dividend ETF
4.65%
Franklin Income Focus ETF
4.56%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil16.09%
FT Vest DJIA Dogs 10 Target Income ETF
Anteil10.79%
First Trust NASDAQ Pharmaceuticals ETF
Anteil7.94%
Invesco Dow Jones Industrial Average Dividend ETF
Anteil6.94%
First Trust Morningstar Dividend Leaders Index Fund
Anteil5.39%
Coastal Compass 100 ETF
Anteil5.13%
Invesco Pharmaceuticals ETF
Anteil4.96%
VanEck Morningstar Wide Moat Value ETF
Anteil4.73%
Vaneck Durable High Dividend ETF
Anteil4.65%
Franklin Income Focus ETF
Anteil4.56%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 28.91B USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Nov 18, 2025
MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025
Dec 15, 2025
Jan 08, 2026
Dec 15, 2025
Jul 22, 2025
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Oct 07, 2025
Sep 15, 2025
May 27, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025
Jun 16, 2025
Jul 08, 2025
Jun 16, 2025
Jan 28, 2025
MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025
Mar 17, 2025
Apr 07, 2025
Mar 17, 2025
Nov 19, 2024
MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024
Dec 16, 2024
Jan 08, 2025
Dec 16, 2024
Jul 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024
Sep 16, 2024
Oct 07, 2024
Sep 16, 2024
May 29, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024
Jun 17, 2024
Jul 08, 2024
Jun 17, 2024
Jan 23, 2024
MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Apr 05, 2024
Mar 14, 2024
Nov 28, 2023
MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023
Dec 15, 2023
Jan 08, 2024
Dec 14, 2023
Jul 25, 2023
MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Oct 06, 2023
Sep 14, 2023
Mehr Anzeigen

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI